COVID-19 drug developer Adagio plans IPO to cap fast rise

COVID-19 drug developer Adagio plans IPO to cap fast rise

Source: 
BioPharma Dive
snippet: 

Adagio Therapeutics has filed for an initial public offering to support development of an antibody drug meant to treat or prevent infections from SARS-CoV-2 and, potentially, other coronaviruses as well.